Paying, but the payout leaves little room for a miss. A 4.95% yield that pays, but is not comfortably covered on trailing earnings: $0.55125 a quarter, raised 5% on an annualized basis in July 2026, at the $44.55 close on October 23, 2026. The $2.205 indicated payout is about 80% of trailing EPS near $2.76, and about 97% on another trailing basis — both well above PGE's own 60%–70% long-term payout target. Only full-year 2026 guidance of $3.33–$3.53 brings the payout to 62%–66%, inside target. Second-quarter 2026 EPS was $0.64 against a $0.65 consensus, on revenue of $814 million against $839.75 million expected. This is a warn, not a trap: no return-of-capital evidence was found, and the price has not collapsed over the long window — but the margin for an earnings miss is thin, and the shares sit near their $43.26 52-week low, down from a $54.62 high in April 2026.
Key risk: The trailing payout itself: at about 80% of trailing earnings (about 97% on another trailing basis), one soft year consumes nearly all of earnings, and Oregon wildfire, vegetation-management and rate-case costs are already running through results. The dividend depends on guidance being hit, not on a cushion already earned.
Changes if: 2026 earnings miss the $3.33–$3.53 guidance range, the trailing payout stays above 70% for another year, or the dividend is held flat after the July 2026 raise. A cut would move this card from warn to a trap review.
- !Payout-coverage check: Flagged: about 80% of trailing EPS near $2.76 — $2.205 indicated — and about 97% on another trailing basis, versus PGE's own 60%–70% long-term target. Coverage only reaches target on 2026 guidance of $3.33–$3.53, which gives 62%–66%. The dividend is guidance-dependent, not trailing-covered.
- ✓Dividend growth check: Raised 5% on an annualized basis in July 2026, to $0.55125 from the prior rate. Growth is real, but it arrived while the trailing payout was already above target — a raise funded by expected, not yet earned, earnings.
- !Yield-reality check: Flagged, but not a trap: the 4.95% yield is the highest in this batch and the price sits near its 52-week low, yet no return-of-capital evidence was found and the long-window price has not collapsed (about 7% over 10 years). High yield plus high payout earns a warn and a watch, not trap treatment.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.